Back to Search
Start Over
Value for Money in H1N1 Influenza: A Systematic Review of the Cost-Effectiveness of Pandemic Interventions.
- Source :
-
Value in Health . Jun2017, Vol. 20 Issue 6, p819-827. 9p. - Publication Year :
- 2017
-
Abstract
- <bold>Background: </bold>The 2009 A/H1N1 influenza pandemic generated additional data and triggered new studies that opened debate over the optimal strategy for handling a pandemic. The lessons-learned documents from the World Health Organization show the need for a cost estimation of the pandemic response during the risk-assessment phase. Several years after the crisis, what conclusions can we draw from this field of research?<bold>Objective: </bold>The main objective of this article was to provide an analysis of the studies that present cost-effectiveness or cost-benefit analyses for A/H1N1 pandemic interventions since 2009 and to identify which measures seem most cost-effective.<bold>Methods: </bold>We reviewed 18 academic articles that provide cost-effectiveness or cost-benefit analyses for A/H1N1 pandemic interventions since 2009. Our review converts the studies' results into a cost-utility measure (cost per disability-adjusted life-year or quality-adjusted life-year) and presents the contexts of severity and fatality.<bold>Results: </bold>The existing studies suggest that hospital quarantine, vaccination, and usage of the antiviral stockpile are highly cost-effective, even for mild pandemics. However, school closures, antiviral treatments, and social distancing may not qualify as efficient measures, for a virus like 2009's H1N1 and a willingness-to-pay threshold of $45,000 per disability-adjusted life-year. Such interventions may become cost-effective for severe crises.<bold>Conclusions: </bold>This study helps to shed light on the cost-utility of various interventions, and may support decision making, among other criteria, for future pandemics. Nonetheless, one should consider these results carefully, considering these may not apply to a specific crisis or country, and a dedicated cost-effectiveness assessment should be conducted at the time. [ABSTRACT FROM AUTHOR]
- Subjects :
- *H1N1 influenza
*PANDEMICS
*COST effectiveness
*PREVENTION of epidemics
*INFLUENZA prevention
*INFLUENZA epidemiology
*ANTIVIRAL agents
*PREVENTION of communicable diseases
*EPIDEMICS
*IMMUNIZATION
*INFLUENZA
*INFLUENZA vaccines
*RISK assessment
*SYSTEMATIC reviews
*QUALITY-adjusted life years
*INFLUENZA A virus, H1N1 subtype
Subjects
Details
- Language :
- English
- ISSN :
- 10983015
- Volume :
- 20
- Issue :
- 6
- Database :
- Academic Search Index
- Journal :
- Value in Health
- Publication Type :
- Academic Journal
- Accession number :
- 123372900
- Full Text :
- https://doi.org/10.1016/j.jval.2016.05.005